Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Brain Cancer Clear all
Recruiting No phase listed Observational

International Rare Brain Tumor Registry

NCT05697874
View directory record Official record
Conditions
Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 45 Years
Enrollment
5,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

NCT02644460
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
Interventions
Abemaciclib
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 5, 2026, 1:29 AM EDT
Terminated Phase 1 Interventional

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

NCT04963413
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 5, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

NCT00550654
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

NCT00820222
View directory record Official record
Conditions
Metastases, Brain
Interventions
capecitabine, lapatinib, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 5, 2026, 1:29 AM EDT
Completed No phase listed Observational

A Complex Contraception Registry

NCT02219269
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

NCT00054756
View directory record Official record
Conditions
Healthy, Pituitary Disease, Thyroid Disease
Interventions
TRH (Thyrotropin Releasing Hormone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 5, 2026, 1:29 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Withdrawn No phase listed Observational

Intraoperative Optical Imaging of Brain Function

NCT00632437
View directory record Official record
Conditions
Brain Tumor
Interventions
Speckle-Contrast Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 5, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

Panitumumab and Irinotecan for Malignant Gliomas

NCT01017653
View directory record Official record
Conditions
Malignant Glioma of Brain
Interventions
Irinotecan, Panitumumab
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 5, 2026, 1:29 AM EDT
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

NCT00003241
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
phenylacetate
Drug
Lead sponsor
Texas Children's Cancer Center
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 5, 2026, 1:29 AM EDT
Recruiting Phase 2 Interventional

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions
Datopotamab Deruxtecan
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

NCT04516070
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Completed No phase listed Observational

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

NCT00006342
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma
Interventions
chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
Genetic
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 5, 2026, 1:29 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

NCT05045027
View directory record Official record
Conditions
Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
Interventions
Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme

NCT00006386
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, radiation therapy, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
217
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 5, 2026, 1:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 1:29 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 5, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

NCT00929669
View directory record Official record
Conditions
Gonadotroph Adenomas
Interventions
pasireotide LAR
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Recurrent Malignant Glioma

NCT00002986
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, topotecan hydrochloride
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
2
States / cities
Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 5, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

NCT00905060
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Temozolomide, Standard Surgical Resection
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 5, 2026, 1:29 AM EDT